LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
Patent Owner
Stats
- 25 US PATENTS IN FORCE
- 10 US APPLICATIONS PENDING
- Jan 23, 2018 most recent publication
Details
- 25 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 808 Total Citation Count
- Jan 27, 1993 Earliest Filing
- 39 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2018/0016,345 LIGHT INHIBITORS FOR SCLERODERMA AND SKIN FIBROTIC DISEASE TREATMENTFeb 05, 16Jan 18, 18[A61K, C07K]
2017/0184,612 USE OF LEUKOCYTES AND NOVEL BIOMARKERS IN THE DIAGNOSIS, CONFIRMATION, AND TREATMENT OF A NEUROLOGICAL DISORDERApr 03, 15Jun 29, 17[A61K, G01N]
2017/0058,037 LIGHT INHIBITORS FOR ASTHMA, LUNG AND AIRWAY INFLAMMATION, RESPIRATORY, INTERSTITIAL, PULMONARY AND FIBROTIC DISEASE TREATMENTOct 14, 16Mar 02, 17[A61K, C07K]
2016/0075,753 MODULATION OF REGULATORY T CELL FUNCTION VIA PROTEIN KINASE C-etaApr 30, 14Mar 17, 16[C12N, C07K]
2015/0110,819 T CELL EPITOPES FROM COCKROACH AND METHODS OF MAKING AND USING SAMEMay 03, 13Apr 23, 15[A61K, G01N, C07K]
2015/0023,992 TIMOTHY GRASS ALLERGENS AND METHODS AND USES FOR IMMUNE RESPONSE MODULATIONFeb 07, 13Jan 22, 15[C07K]
2014/0004,151 Antigens and Epitopes Derived From Mycobacterium TuberculosisOct 01, 12Jan 02, 14[A61K, C07K]
2013/0108,602 METHODS AND USES OF NUR77 AND NUR77 AGONISTS TO MODULATE MACROPHAGES AND MONOCYTES, AND TREAT INFLAMMATION, INFLAMMATORY DISEASE AND CARDIOVASCULAR DISEASEOct 05, 12May 02, 13[A61K]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9873744 Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying sameJan 13, 15Jan 23, 18[A61K, C07K]
9771419 Antagonistic human light-specific human monoclonal antibodiesFeb 02, 15Sep 26, 17[A61K, C07K]
9700606 HVEM/BTLA, HVEM/CD 160 and HVEM/gD cis complexes and methods of useJul 08, 09Jul 11, 17[A61K, C07K]
9694058 Light-mediated anti-cell proliferative compositions and methodsOct 25, 07Jul 04, 17[A61K, C12N, C07K]
9447172 Vaccinia virus H3L and B5R specific monoclonal antibodies and methods of making and using sameDec 27, 13Sep 20, 16[A61K, C07K]
9301994 LIGHT inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatmentJan 20, 11Apr 05, 16[A61K]
8974787 Antagonistic human light-specific human monoclonal antibodiesMay 08, 13Mar 10, 15[A61K, C07K]
8956615 Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying sameSep 13, 13Feb 17, 15[A61K, C07K]
8623370 Vaccinia virus H3L and B5R specific monoclonal antibodies and methods of making and using sameOct 06, 08Jan 07, 14[A61K]
8551477 Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying sameDec 19, 11Oct 08, 13[A61K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2016/0287,696 PAN POLLEN IMMUNOGENS AND METHODS AND USES FOR IMMUNE RESPONSE MODULATIONAbandonedNov 20, 14Oct 06, 16[A61K, C07K]
2015/0150,960 PROTECTION AGAINST DENGUE VIRUS AND PREVENTION OF SEVERE DENGUE DISEASEAbandonedJun 25, 12Jun 04, 15[A61K, C12N]
2015/0119,333 METHODS OF INHIBITING ADVERSE CARDIAC EVENTS AND TREATING ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE USING GALECTIN-3 BINDING PROTEIN (GAL-3BP, BTBD17B, MAC-2 BINDING PROTEIN)AbandonedSep 18, 13Apr 30, 15[A61K]
2015/0004,189 EPITOPES FROM ALLERGEN PROTEINS AND METHODS AND USES FOR IMMUNE RESPONSE MODULATIONAbandonedFeb 07, 13Jan 01, 15[A61K, G01N]
2014/0186,372 COMPOSITIONS TARGETING PKC-THETA AND USES AND METHODS OF TREATING PKC-THETA PATHOLOGIES, ADVERSE IMMUNE RESPONSES AND DISEASESAbandonedJun 15, 12Jul 03, 14[G01N]
2014/0134,647 NOVEL CRYSTAL STRUCTURE AND LIGAND BINDING SITES OF TRAIL RECEPTORAbandonedOct 31, 13May 15, 14[G01N]
2013/0202,634 Dengue Virus (DV) Polypeptide Sequences, T Cell Epitopes and Methods and Uses ThereofAbandonedDec 18, 12Aug 08, 13[C07K]
2013/0171,164 COMPOSITIONS AND METHODS OF MODULATING RECEPTOR PROTEIN TYROSINE PHOSPHATASESAbandonedAug 02, 12Jul 04, 13[C12Q]
2013/0095,127 METHODS OF INHIBITING INFLAMMATION AND INFLAMMATORY DISEASES USING Gal-3BP (BTBD17B, LGALS3BP, GALECTIN-3 BINDING PROTEIN, MAC-2 BINDING PROTEIN)AbandonedSep 26, 12Apr 18, 13[A61K, C07K]
2013/0084,293 HISTAMINE-RELEASING FACTOR (HRF), HRF-RECEPTOR AND METHODS OF MODULATING INFLAMMATIONAbandonedSep 28, 12Apr 04, 13[A61K, C07K]
2012/0251,505 HUMAN LYMPHOID TISSUE INDUCER (LTi) CELL COMPOSITIONS AND METHODS OF USEAbandonedSep 03, 10Oct 04, 12[A61K, C12Q, C12N, G01N, A61P, C40B]
2012/0121,590 METHODS OF INHIBITING ADVERSE CARDIAC EVENTS AND TREATING ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE USING GALECTIN-3 BINDING PROTEIN (GAL-3BP, BTBD17B, MAC-2 BINDING PROTEIN)AbandonedApr 16, 10May 17, 12[A61K, C12Q, G01N, A61P, C07K]
2011/0171,242 LIGAND FOR HERPES SIMPLEX VIRUS ENTRY MEDIATOR AND METHODS OF USEAbandonedJul 06, 09Jul 14, 11[A61K, C12N, A61P, C07K]
2011/0150,914 COMPOSITIONS AND METHODS FOR DENGUE VIRUS (DV) TREATMENT AND VACCINATIONAbandonedJun 09, 09Jun 23, 11[A61K, C07H, C12N, A61P, C07K]
2011/0038,855 TRAIL AND METHODS OF MODULATING T CELL ACTIVITY AND ADAPTIVE IMMUNE RESPONSES USING TRAILAbandonedApr 02, 09Feb 17, 11[A61K, C12N, A61P]
2010/0129,389 METHODS OF MODULATING HVEM, BTLA AND CD160 CIS COMPLEX RESPONSE OR SIGNALING ACTIVITY WITH SOLUBLE LIGHT POLYPEPTIDE SEQUENCESAbandonedAug 03, 09May 27, 10[A61K, A61P]
2009/0136,470 REGULATORY T CELLS AND METHODS OF MAKING AND USING SAMEAbandonedJun 13, 08May 28, 09[A61K]
2009/0136,427 LIGHT Inhibitors For Asthma, Lung and Airway Inflammation, Respiratory, Interstitial, Pulmonary and Fibrotic Disease TreatmentAbandonedSep 18, 08May 28, 09[A61K, A61P]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.